相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer:: The ONCOBELL trial
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
F Cappuzzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
XJ Zhao et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients
D Masuya et al.
BRITISH JOURNAL OF CANCER (2004)
Semi-parametric estimation of the binormal ROC curve for a continuous diagnostic test
TX Cai et al.
BIOSTATISTICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
c-Met: Structure, functions and potential for therapeutic inhibition
PC Ma et al.
CANCER AND METASTASIS REVIEWS (2003)
分享论文
